12. Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in bladder cancer

Bladder cancer is the tenth most common cancer worldwide, accounting for over 500,000 new cancer cases and 200,000 cancer-related deaths per year. In recent years, use of immune checkpoint blockade (ICB) treatments for bladder cancer has become more common and several PD-1/PD-L1 inhibitors have been approved by the FDA for treatment of bladder cancer. However, clinical trials of PD-1/PD-L1 monotherapy show response rates of only ∼30%, indicating many patients are not receiving benefit from ICB treatments.

Source: Cancer Genetics and Cytogenetics - November 1, 2023 Category: Genetics & Stem Cells Authors: Sharon Freshour, Bryan Fisk, Timothy Chen, Haolin Shen, Matthew Mosior, Zachary Skidmore, Catrina Fronick, Jennifer Bolzenius, Obi Griffith, Vivek Arora, Malachi Griffith Source Type: research